| Catalog No. | HP628016 |
|---|
| Species reactivity | Human |
|---|
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| Host species | Humanized |
|---|
| Isotype | IgG1-kappa |
|---|
| Expression system | Mammalian Cells |
|---|
| Clonality | Monoclonal |
|---|
| Target | Drosophila Delta homolog 3, Delta3, Delta-like protein 3, DLL3 |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G purified from cell culture supernatant. |
|---|
| Accession | Q9NYJ7 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS, pH 7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
|---|
| Alternate Names | SC0001-SCX, SC0002, 1613313-01-1 |
|---|
| Background | Rovalpituzumab is a humanized monoclonal antibody against delta-like protein 3 (DLL3). Rovalpituzumab can be used in the synthesis of antibody-drug conjugate (ADC), Rovalpituzumab Tesirine. Rovalpituzumab has activity against small cell lung cancer (SCLC).
• Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer., PMID:37355629
• Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer., PMID:30894499
• DLL3: an emerging target in small cell lung cancer., PMID:31215500
• Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study., PMID:36689692
• AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer., PMID:33203642
• DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms., PMID:35983951
• A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo., PMID:26311731
• IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models., PMID:36951942
• HPN328, a Trispecific T Cell-Activating Protein Construct Targeting DLL3-Expressing Solid Tumors., PMID:38670552
• Clinical Pharmacology Profile of AMG 119, the First Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting Delta-Like Ligand 3 (DLL3), in Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC)., PMID:37694295
|
|---|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
|---|
